Trials / Terminated
TerminatedNCT03292536
Merestinib on Bone Metastases in Subjects With Breast Cancer
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Merestinib | \*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\* Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks |
Timeline
- Start date
- 2018-01-11
- Primary completion
- 2019-06-24
- Completion
- 2019-06-24
- First posted
- 2017-09-25
- Last updated
- 2021-01-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03292536. Inclusion in this directory is not an endorsement.